Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities

Cash Flow Statement

Daily Values

Growth Metrics

Arcadia Biosciences (RKDA) Long-Term Investments (2016)

Arcadia Biosciences filings provide 2 years of Long-Term Investments readings, the most recent being $2.5 million for Q4 2016.

On a quarterly basis, Long-Term Investments fell 87.35% to $2.5 million in Q4 2016 year-over-year; TTM through Dec 2016 was $2.5 million, a 87.35% decrease, with the full-year FY2016 number at $2.5 million, down 87.35% from a year prior.
Long-Term Investments hit $2.5 million in Q4 2016 for Arcadia Biosciences, down from $3.5 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $19.7 million in Q4 2015 to a low of $500000.0 in Q1 2015.